Aspire Biopharma Holdings, Inc. (ASBP)
| Market Cap | 7.39M -93.2% |
| Revenue (ttm) | 1,941 |
| Net Income | -20.54M |
| EPS | -16.59 |
| Shares Out | 5.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 222,430 |
| Open | 1.400 |
| Previous Close | 1.450 |
| Day's Range | 1.400 - 1.592 |
| 52-Week Range | 1.200 - 69.660 |
| Beta | 0.81 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 17, 2026 |
About ASBP
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it i... [Read more]
Financial Performance
Financial StatementsNews
Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief
Collaboration aims to create the first-ever sublingual alprazolam powder, addressing the need for faster-acting anxiety medication. Phase 1 clinical trial of the patent-pending, rapid-onset formulatio...
Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship
BUZZ BOMB™ captures over 400,000 views and a spike in online revenue driven by strategic brand expansion and Ashley Paulson's historic record at the Jackpot Ultra Running Festival. ESTERO, FL / ACCESS...
Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements
Company achieves minimum stockholders' equity rule; Nasdaq confirms matter is closed Aspire maintains listing on the Nasdaq ESTERO, FL / ACCESS Newswire / February 20, 2026 / Aspire Biopharma Holdings...
Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record
ESTERO, FL / ACCESS Newswire / February 19, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company") today announced that its wholly owned subsidiary Buzz Bomb Caffeine Company...
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))
New delivery system targets rapid-onset relief for motion sickness and vertigo, modernizing the $450M global market for the active ingredient in Dramamine®. Meclizine was the top-prescribed antiemetic...
Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors
New independent director Phillip Balatsos brings commercial and capital markets expertise to drive development patent-pending drug delivery platform ESTERO, FL / ACCESS Newswire / February 13, 2026 / ...
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))
New sublingual delivery system designed to provide more rapid relief from nausea caused by cancer medicines Ondansetron, currently sold under the brand name Zofran®, was the 53rd most commonly prescri...
Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements
ESTERO, FLORIDA / ACCESS Newswire / February 11, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending d...
Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closed ESTERO, FLORIDA / ACCESS Newswire / February 10, 2026 / Aspire Biopharma Holdings, Inc. (N...
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit
ESTERO, FL / ACCESS Newswire / February 5, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), wholly owned subsidiary, Buzz Bomb Caffeine Company, a marketer of a propri...
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution
ESTERO, FL / ACCESS Newswire / February 3, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), wholly owned subsidiary, Buzz Bomb Caffeine Company, today announced a stra...
Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin
Microsize brings over thirty years of expertise in specialized particle size engineering for the pharmaceutical industry, from pre-clinical development to full-scale GMP commercial manufacturing. ESTE...
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks
New sublingual delivery system designed to enhance bioavailability and avoid gastric side effects many patients experience with clopidogrel. Clopidogrel, currently sold under the brand name Plavix®, w...
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity
Strategic inventory of 100,000 20-packs now available to meet increasing demand for rapid-onset sublingual caffeine technology ESTERO, FL / ACCESS Newswire / January 22, 2026 / Aspire Biopharma Holdin...
Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign
New streamlined, mobile-optimized shopping experience, allows consumers to purchase BUZZ BOMB™ directly, access exclusive promotions and engage with the brand through educational and lifestyle content...
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief
New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and generalized anxiety disorders Alprazolam, sold under the brand name Xanax® among others, ...
Aspire Biopharma Announces Reverse Stock Split
ESTERO, FL / ACCESS Newswire / January 14, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug de...
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)
FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject clinical trial ESTERO, FL / ACCESS Newswire / January 7, 2026 / Aspire Biopharma Hol...
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine
A highly decorated endurance athlete, Ashley embodies the grit, energy, and rapid performance that BUZZ BOMB® was designed to support BUZZ BOMB™ will power Ashley's elite training, recovery, and lifes...
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
ESTERO, FL / ACCESS Newswire / December 12, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, re...
Aspire Biopharma Provides Q3 2025 Business Update
ESTERO, FL / ACCESS Newswire / December 4, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, tod...
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
ESTERO, FLORIDA / ACCESS Newswire / December 2, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology...
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member
ESTERO, FL / ACCESS Newswire / November 26, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, ha...
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin
ESTERO, FL / ACCESS Newswire / November 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today...
Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform
ESTERO, FLORIDA / ACCESS Newswire / October 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, t...